The United Kingdom and the United States have announced a significant bilateral deal that will maintain zero import taxes on British medicine shipments being sold in the US market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has agreed to boost spending on drugs through the public health system. This move secures that import taxes on these vital exports will be held at nothing for a period of three years.
This development is in response to earlier statements to significantly raise import taxes on patented pharmaceutical products, with potential rates discussed up to double the cost.
"This agreement with the United Kingdom reinforces the worldwide climate for cutting-edge drugs and brings long-overdue equity to transatlantic pharmaceutical trade," an announcement said.
Commercial Significance
Medicines are one of the the United Kingdom's most significant export categories to the America, which is clearly the biggest buyer for large British pharmaceutical firms.
Trade data reveal that in the one-year period prior to the third quarter, the UK shipped drugs worth over eleven billion pounds to the US. This figure represented 17.4% of total UK exports in that period.
"This agreement secures work, boosts funding and facilitates the UK to emerge as a global hub for medical research," a government official remarked.
Specific British Pledges
The pact involves several key commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it deems new medicines to be unaffordable by a quarter.
- Higher Drug Budget: There is a target to raise total health service expenditure on medicines from 0.3% of GDP to 0.6 percent over the next decade.
- Rebate Cap: The percentage drug companies must return to the NHS to prevent overspending will be restricted at fifteen percent. Previously, rebates were more than twenty percent.
Broader Context
This agreement follows a long-running row between the pharmaceutical industry and the British authorities over medicine costs and NHS adoption.
These tensions were intensified by arguments that US patients were paying a premium for the same drugs than people in the UK and Europe.
In recent months, several major drug company projects in the UK have been delayed or scrapped, while multi-billion-dollar investments have been pledged toward projects in the United States.
A senior figure acknowledged that the NHS had to invest a greater share on medicines, noting that its expenditure on drugs had declined as a share of its total funding over the previous ten-year period.
